Suzetrigine

DRUG16 trials

Sponsors

Vertex Pharmaceuticals Incorporated, Latigo Biotherapeutics, Hospital for Special Surgery, New York, Mayo Clinic, University of California, Los Angeles

Conditions

Acute PainAcute Pain, PostoperativeBreast DiseaseDiabetic Peripheral Neuropathic PainDiabetic Peripheral NeuropathyJOURNAVXMultimodal AnalgesiaNav 1.8

Phase 1

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

CompletedNCT06336096

Vertex Pharmaceuticals IncorporatedPain

Start: 2024-03-28End: 2024-06-19Updated: 2024-07-19

Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants

CompletedNCT06820307

Vertex Pharmaceuticals IncorporatedPain

Start: 2025-02-25End: 2025-04-29Updated: 2025-05-29

Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants

RecruitingNCT07378865

Vertex Pharmaceuticals IncorporatedPain

Start: 2026-02-13End: 2027-02-26Target: 12Updated: 2026-02-27

Phase 2

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

CompletedNCT05660538

Vertex Pharmaceuticals IncorporatedDiabetic Peripheral Neuropathy

Start: 2022-12-20End: 2023-10-25Updated: 2025-07-01

This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third Molars

CompletedNCT06774625

Latigo BiotherapeuticsAcute Pain, Postoperative

Start: 2024-12-19End: 2025-08-08Updated: 2026-01-09

Phase 3

A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain

CompletedNCT05661734

Vertex Pharmaceuticals IncorporatedPain

Start: 2023-01-09End: 2023-12-12Updated: 2025-07-01

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

RecruitingNCT06628908

Vertex Pharmaceuticals IncorporatedDiabetic Peripheral Neuropathic Pain

Start: 2024-10-01End: 2027-05-31Target: 1100Updated: 2026-03-31

Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)

Active, not recruitingNCT06696443

Vertex Pharmaceuticals IncorporatedDiabetic Peripheral Neuropathic Pain

Start: 2024-12-18End: 2027-01-25Updated: 2026-01-29

Suzetrigine in Total Hip Arthroplasty

RecruitingNCT07226700

Hospital for Special Surgery, New YorkJOURNAVX, Multimodal Analgesia, Nav 1.8 +14

Start: 2025-11-03End: 2028-11-01Target: 210Updated: 2026-01-29

Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy

RecruitingNCT07231419

Vertex Pharmaceuticals IncorporatedDiabetic Peripheral Neuropathic Pain

Start: 2025-11-21End: 2027-04-06Target: 734Updated: 2026-04-01

Evaluating Suzetrigine for Pain Control Following TKA

Not yet recruitingNCT07357376

AdventHealthPostoperative Pain Following Knee Arthroplasty

Start: 2026-03-01End: 2026-08-01Target: 210Updated: 2026-01-22

Phase 4

A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries

CompletedNCT06887972

Vertex Pharmaceuticals IncorporatedAcute Pain

Start: 2025-03-21End: 2025-11-07Updated: 2025-12-15

A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries

CompletedNCT06887959

Vertex Pharmaceuticals IncorporatedAcute Pain

Start: 2025-03-27End: 2025-11-10Updated: 2025-12-15

A Study Of Opioid Avoidance In Surgery Through Integrating Suzetrigine

Not yet recruitingNCT07257133

Mayo ClinicPost Operative Pain

Start: 2026-03-31End: 2028-03-31Target: 40Updated: 2025-12-02

Suzetrigine Versus Usual-care Opioids for Postop Pain in Sports

Not yet recruitingNCT07355166

University of California, Los AngelesPostoperative Pain Management

Start: 2026-02-01End: 2026-07-01Target: 140Updated: 2026-01-21

Suzetrigine for Non-Mastectomy Breast Surgery

Not yet recruitingNCT07463430

University of California, San DiegoBreast Disease, Pain, Acute Postoperative

Start: 2026-03-30End: 2027-09-30Target: 120Updated: 2026-03-24

Related Papers

Suzetrigine, a Non-Opioid NaV1.8 Inhibitor With Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute Pain

Journal of Pain Research2025-03-0126 citations